These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 17400285)

  • 1. Overexpression of folate binding protein and mesothelin are associated with uterine serous carcinoma.
    Dainty LA; Risinger JI; Morrison C; Chandramouli GV; Bidus MA; Zahn C; Rose GS; Fowler J; Berchuck A; Maxwell GL
    Gynecol Oncol; 2007 Jun; 105(3):563-70. PubMed ID: 17400285
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Microarray analysis of endometrial carcinomas and mixed mullerian tumors reveals distinct gene expression profiles associated with different histologic types of uterine cancer.
    Maxwell GL; Chandramouli GV; Dainty L; Litzi TJ; Berchuck A; Barrett JC; Risinger JI
    Clin Cancer Res; 2005 Jun; 11(11):4056-66. PubMed ID: 15930340
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overexpression of folate binding protein is associated with shortened progression-free survival in uterine adenocarcinomas.
    Allard JE; Risinger JI; Morrison C; Young G; Rose GS; Fowler J; Berchuck A; Maxwell GL
    Gynecol Oncol; 2007 Oct; 107(1):52-7. PubMed ID: 17582475
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of the folate receptor genes FOLR1 and FOLR3 differentiates ovarian carcinoma from breast carcinoma and malignant mesothelioma in serous effusions.
    Yuan Y; Nymoen DA; Dong HP; Bjørang O; Shih IeM; Low PS; Trope' CG; Davidson B
    Hum Pathol; 2009 Oct; 40(10):1453-60. PubMed ID: 19454358
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor suppressor gene, cell surface adhesion molecule, and multidrug resistance in Müllerian serous carcinomas: clinical divergence without immunophenotypic differences.
    Soslow RA; Slomovitz BM; Saqi A; Baergen RN; Caputo TA
    Gynecol Oncol; 2000 Dec; 79(3):430-7. PubMed ID: 11104615
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunohistochemical overexpression of p16 and p53 in uterine serous carcinoma and ovarian high-grade serous carcinoma.
    Chiesa-Vottero AG; Malpica A; Deavers MT; Broaddus R; Nuovo GJ; Silva EG
    Int J Gynecol Pathol; 2007 Jul; 26(3):328-33. PubMed ID: 17581420
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression status of folate receptor alpha is significantly correlated with prognosis in non-small-cell lung cancers.
    Iwakiri S; Sonobe M; Nagai S; Hirata T; Wada H; Miyahara R
    Ann Surg Oncol; 2008 Mar; 15(3):889-99. PubMed ID: 18181001
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer.
    Zorn KK; Bonome T; Gangi L; Chandramouli GV; Awtrey CS; Gardner GJ; Barrett JC; Boyd J; Birrer MJ
    Clin Cancer Res; 2005 Sep; 11(18):6422-30. PubMed ID: 16166416
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patterns of gene expression in different histotypes of epithelial ovarian cancer correlate with those in normal fallopian tube, endometrium, and colon.
    Marquez RT; Baggerly KA; Patterson AP; Liu J; Broaddus R; Frumovitz M; Atkinson EN; Smith DI; Hartmann L; Fishman D; Berchuck A; Whitaker R; Gershenson DM; Mills GB; Bast RC; Lu KH
    Clin Cancer Res; 2005 Sep; 11(17):6116-26. PubMed ID: 16144910
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Utility of p16 expression for distinction of uterine serous carcinomas from endometrial endometrioid and endocervical adenocarcinomas: immunohistochemical analysis of 201 cases.
    Yemelyanova A; Ji H; Shih IeM; Wang TL; Wu LS; Ronnett BM
    Am J Surg Pathol; 2009 Oct; 33(10):1504-14. PubMed ID: 19623034
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diffuse mesothelin expression correlates with prolonged patient survival in ovarian serous carcinoma.
    Yen MJ; Hsu CY; Mao TL; Wu TC; Roden R; Wang TL; Shih IeM
    Clin Cancer Res; 2006 Feb; 12(3 Pt 1):827-31. PubMed ID: 16467095
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Claudin 1 differentiates endometrioid and serous papillary endometrial adenocarcinoma.
    Sobel G; Németh J; Kiss A; Lotz G; Szabó I; Udvarhelyi N; Schaff Z; Páska C
    Gynecol Oncol; 2006 Nov; 103(2):591-8. PubMed ID: 16797678
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Opposite alterations of DNA methyltransferase gene expression in endometrioid and serous endometrial cancers.
    Xiong Y; Dowdy SC; Xue A; Shujuan J; Eberhardt NL; Podratz KC; Jiang SW
    Gynecol Oncol; 2005 Mar; 96(3):601-9. PubMed ID: 15721400
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human kallikrein 6: a new potential serum biomarker for uterine serous papillary cancer.
    Santin AD; Diamandis EP; Bellone S; Soosaipillai A; Cane S; Palmieri M; Burnett A; Roman JJ; Pecorelli S
    Clin Cancer Res; 2005 May; 11(9):3320-5. PubMed ID: 15867230
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The frequency of p53, K-ras mutations, and microsatellite instability differs in uterine endometrioid and serous carcinoma: evidence of distinct molecular genetic pathways.
    Lax SF; Kendall B; Tashiro H; Slebos RJ; Hedrick L
    Cancer; 2000 Feb; 88(4):814-24. PubMed ID: 10679651
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Distinguishing breast carcinoma from Müllerian serous carcinoma with mammaglobin and mesothelin.
    Kanner WA; Galgano MT; Stoler MH; Mills SE; Atkins KA
    Int J Gynecol Pathol; 2008 Oct; 27(4):491-5. PubMed ID: 18753974
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overexpression of claudin-3 and claudin-4 receptors in uterine serous papillary carcinoma: novel targets for a type-specific therapy using Clostridium perfringens enterotoxin (CPE).
    Santin AD; Bellone S; Marizzoni M; Palmieri M; Siegel ER; McKenney JK; Hennings L; Comper F; Bandiera E; Pecorelli S
    Cancer; 2007 Apr; 109(7):1312-22. PubMed ID: 17326053
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Human pituitary tumor transforming gene 1 expression in ovarian carcinoma and its clinical significance].
    Cheng YX; Feng J; Zhang XY; Fu TY; Yao Y
    Ai Zheng; 2004 Sep; 23(9):1026-30. PubMed ID: 15363195
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular alterations in uterine serous carcinoma.
    Hayes MP; Ellenson LH
    Gynecol Oncol; 2010 Feb; 116(2):286-9. PubMed ID: 20109727
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Microsatellite instability and mismatch repair protein defects in ovarian epithelial neoplasms in patients 50 years of age and younger.
    Jensen KC; Mariappan MR; Putcha GV; Husain A; Chun N; Ford JM; Schrijver I; Longacre TA
    Am J Surg Pathol; 2008 Jul; 32(7):1029-37. PubMed ID: 18469706
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.